Since President Trump took office earlier this year, US healthcare policy has been in flux, with many proposals and announcements generating headlines but few resulting in concrete changes. Most recently, on May 20, 2025, the Department of Health and Human Services and the Centers for Medicare & Medicaid Services announced steps to implement the “Most-Favored-Nation” pricing model, which aims to lower US drug prices by tying them to those paid in other high-income countries. However, it remains to be seen whether it will lead to meaningful reform or encounter hurdles that have stalled other initiatives (citation: https://www.hhs.gov/press-room/cms-mfn-lower-us-drug-prices.html).
Discover the key takeaways from OPEN Health’s latest whitepaper The Potential Impact of the New Presidential Administration on the Future of the Inflation Reduction Act and Broader Healthcare Policy:
- Review of President Trump’s healthcare policies during his first term: Attempts to repeal the Affordable Care Act (ACA), drug pricing initiatives, and Medicare and Medicaid policies.
- A look into the future of the Inflation Reduction Act (IRA) and broader healthcare policy in the US: The potential impact of the incoming administration on the healthcare provisions of the IRA and other statements by President Trump focused on healthcare policy.
OPEN Health contributors:
We are excited to share our latest thinking with you.
Please fill out the form to download the whitepaper.
"*" indicates required fields
At OPEN Health, we connect visionary minds, pioneering science, and advanced technology to drive real impact.
By uniting people, science, and technology, we activate new opportunities for biopharma innovation. Our expertise across medical affairs and market access unlocks faster, smarter routes to market. We are committed to improving patient outcomes worldwide.
